Medication Guide

Prescription Info

Instructions for Use

Treating patients on
HUMIRA (adalimumab)?
Consider a biosimilar called HADLIMA. HADLIMA is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients.
Limitations of Use:
The effectiveness of HADLIMA has not been established in patients who have lost response to or were intolerant to tumor necrosis factor (TNF) blockers. Dov, a real patient with moderately
to severely active ulcerative colitis who switched from HUMIRA (adalimumab)
to HADLIMA, an FDA-approved interchangeable biosimilar to HUMIRA. Cost and coverage for HADLIMA is dependent on the terms and conditions
of individual insurance benefits,
including any applicable deductible,
co-insurance, or co-payment. Based on analysis of actual patient
claims processed from July 2023 to August 2024, with the average
out-of-pocket costs being $215 vs $48
for HUMIRA and HADLIMA, respectively. Consider which patients may benefit
from switching to HADLIMA today.